TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01606345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valrubicin
Description: Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
Study: NCT05691296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home training
Description: Letter Chart Accomodative Rock Training for 2 minutes each time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School training
Description: Letter Chart Accomodative Rock Training for 2 minutes each time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School training
Description: Letter Chart Accomodative Rock Training for 2 minutes each time
Study: NCT01392976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
Study: NCT02240199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Infusion
Description: Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative Intravenous Lidocaine Infusion
Description: Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perioperative Pregabalin
Description: Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Pregabalin
Description: Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Pregabalin Placebo
Description: Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative Pregabalin Placebo
Description: Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Placebo Infusion
Description: Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Intravenous Lidocaine Placebo Infusion
Description: Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
Study: NCT01312688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Hemodynamic Therapy in Sepsis
Description: Early Goal Directed Hemodynamic Therapy according to the SSC guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Early Goal Directed Hemodynamic Therapy in Sepsis
Description: Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
Study: NCT02568150

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Single group, open-label
Study: NCT03249233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZenLens™
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZenLens™
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zen™ RC
Description: The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zen™ RC
Description: The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Study: NCT00387075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT and SPECT imaging
Description: This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT
Description: SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
Study: NCT00887224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate sustained release 50 mg
Description: 50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate sustained release 25 mg
Description: 25 mg tablet for taper, once daily for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
Study: NCT04295642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVL-751
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-751
Description: Oral tablet
Study: NCT03970096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01555138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol is delivered via a SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol/fluticasone is delivered via a MDDPI
Study: NCT03779672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride 10 mg
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine Hydrochloride 10 mg
Description: * Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps
Study: NCT02117310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
Study: NCT04061759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.
Description: Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.
Description: Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.
Description: Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.
Description: Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
Study: NCT03244800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously once daily for 49 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously once daily for 49 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously once daily for 49 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously once daily for 49 days.
Study: NCT02103166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine bromide
Description: 20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: 100 ml of physiological serum (0.9% NaCl).
Study: NCT02903875

Intervention type: OTHER
Intervention: Patient therapeutic education (PTE) programme
Study: NCT03822468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg tablets for oral use QD continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1 mg tablets for oral use QD continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets for oral use QD continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg tablets for oral use QD continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Study: NCT01098604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 32mm ceramic head group
Description: we performed THA using 32mm ceramic head in this group.
Study: NCT03164096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
Study: NCT01220882

Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Radiographic skeletal age assessment
Description: bone age assessment from the elbow lateral radiograph
Study: NCT03690115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
Study: NCT01967251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Udenafil placebo-matching tablets
Study: NCT02903875

Intervention type: OTHER
Intervention: Patient therapeutic education (PTE) programme

Intervention type: OTHER
Intervention: Patient therapeutic education (PTE) programme
Study: NCT01384968

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beetroot juice
Description: 170 mL beetroot juice (Beet It, James White drinks Ltd).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beetroot juice
Description: 170 mL beetroot juice (Beet It, James White drinks Ltd).
Study: NCT00221598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodialysis with different dialysate temperatures
Description: Haemodialysis with different dialysate temperatures is used.
Study: NCT02446990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: 5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
Study: NCT00323115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell
Description: Vaccine given by cervical lymph node injection 3 times every other week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT is standard of care (SOC) post surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Vaccine given cervical lymphnode injection 3 times every other week
Study: NCT02894931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monosaccharides
Description: The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Disaccharides
Description: The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Disaccharides
Description: The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Disaccharides
Description: The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
Study: NCT01006057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
Study: NCT02894931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners
Description: The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners
Description: The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners
Description: The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners
Description: The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control- water
Description: Chilled water flavored with lemon juice as control
Study: NCT02596191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological record

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological record

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle MRI
Study: NCT01006057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
Study: NCT03258398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: eFT508 will be taken orally (PO) twice a day (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: eFT508 will be taken orally (PO) twice a day (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: eFT508 will be taken orally (PO) twice a day (bid).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter